Compare BHE & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHE | PBLS |
|---|---|---|
| Founded | 1979 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.4B |
| IPO Year | 1996 | 2026 |
| Metric | BHE | PBLS |
|---|---|---|
| Price | $78.03 | $28.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $55.00 | N/A |
| AVG Volume (30 Days) | ★ 552.2K | 545.1K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $2,659,108,000.00 | N/A |
| Revenue This Year | $7.03 | N/A |
| Revenue Next Year | $6.57 | N/A |
| P/E Ratio | $215.63 | ★ N/A |
| Revenue Growth | ★ 0.11 | N/A |
| 52 Week Low | $34.44 | $25.56 |
| 52 Week High | $100.41 | $33.65 |
| Indicator | BHE | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 52.17 |
| Support Level | $42.45 | $26.96 |
| Resistance Level | $88.27 | $30.90 |
| Average True Range (ATR) | 4.51 | 2.39 |
| MACD | -1.49 | -0.05 |
| Stochastic Oscillator | 18.33 | 30.56 |
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.